A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis Based Medicine Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215)

Journal of Cannabis Therapeutics

Volumn 3, Issue 4, 2003, Pages 121-152

  Guy, G W ^a   Robson, P J ^a  

^a Porton Down Science Park   (United Kingdom)

Author keywords

Alternative delivery systems; Botanical extracts; Cannabidiol; Cannabinoids; Cannabis; Harm reduction; Medical marijuana; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics; THC

Indexed keywords

11 HYDROXYDRONABINOL; ALCOHOL; CANNABIDIOL; CANNABINOID; CANNABIS; DRONABINOL; DRUG METABOLITE; FLAVORING AGENT; PEPPERMINT; PLACEBO; PROPYLENE GLYCOL; TETRAHYDROCANNABINOL;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ELECTROCARDIOGRAM; EXPERIMENTAL DESIGN; EYE DISEASE; GASTROINTESTINAL DISEASE; GLOSSITIS; HEADACHE; HEMATOLOGICAL PARAMETERS; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INJECTION SITE; LETHARGY; MALE; MOUTH DISEASE; MUSCLE TWITCH; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PAIN; PALATABILITY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUMP; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINITIS; RIB FRACTURE; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYNCOPE; THORAX DISEASE; THROAT DISEASE; TONGUE DISEASE; TOXICITY TESTING; VASCULAR DISEASE; VISUAL IMPAIRMENT; VOLUNTEER; VOMITING;

EID: 1542346972     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v03n04_02     Document Type: Article

References (10)

1. Agurell, S., M. Halldin, J. E. Lindgren, A. Ohlsson, M. Widman, H. Gillespie, and L. Hollister. 1986. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 (1):21-43.
2. Association, British Medical. 1997. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers.
3. Baker, P. B., T. A. Gough, and B. J. Taylor. 1983. The physical and chemical features of Cannabis plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin-Part II: Second generation studies. Bull Narc 35 (1):51-62.
4. Lords, House of. 1998. Cannabis: The scientific and medical evidence. London: House of Lords Select Committee on Science and Technology, Stationery Office.
5. Maykut, M. O. 1985. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 9 (3):209-38.
6. McPartland, J. M., and E. B. Russo. 2001. Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Therap 1(3-4):103-132.
7. Pharmaceuticals, GW. 2002. Investigators brochure for cannabis based medicine extract (CBME). Porton Down: GW Pharmaceuticals.
8. Portenoy, R. K. 1990. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 5 (1 Suppl):S46-62.
9. Porter, J., and H. Jick. 1980. Addiction rare in patients treated with narcotics. N Engl J Med 302 (2):123.
10. Whittle, B. A., G. W. Guy, and P. Robson. 2001. Prospects for new cannabis-based prescription medicines. J Cannabis Therap 1(3-4):183-205.